JP2018510213A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510213A5
JP2018510213A5 JP2017564947A JP2017564947A JP2018510213A5 JP 2018510213 A5 JP2018510213 A5 JP 2018510213A5 JP 2017564947 A JP2017564947 A JP 2017564947A JP 2017564947 A JP2017564947 A JP 2017564947A JP 2018510213 A5 JP2018510213 A5 JP 2018510213A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
von willebrand
treatment
life
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017564947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510213A (ja
JP6704420B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/054650 external-priority patent/WO2016142289A1/en
Publication of JP2018510213A publication Critical patent/JP2018510213A/ja
Publication of JP2018510213A5 publication Critical patent/JP2018510213A5/ja
Application granted granted Critical
Publication of JP6704420B2 publication Critical patent/JP6704420B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017564947A 2015-03-06 2016-03-04 フォンヴィレブランド因子の半減期を改善するための化合物 Expired - Fee Related JP6704420B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15158088 2015-03-06
EP15158088.3 2015-03-06
PCT/EP2016/054650 WO2016142289A1 (en) 2015-03-06 2016-03-04 Compounds for improving the half-life of von willebrand factor

Publications (3)

Publication Number Publication Date
JP2018510213A JP2018510213A (ja) 2018-04-12
JP2018510213A5 true JP2018510213A5 (enExample) 2019-04-04
JP6704420B2 JP6704420B2 (ja) 2020-06-03

Family

ID=52629453

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564947A Expired - Fee Related JP6704420B2 (ja) 2015-03-06 2016-03-04 フォンヴィレブランド因子の半減期を改善するための化合物

Country Status (12)

Country Link
US (1) US20180043012A1 (enExample)
EP (1) EP3265489B1 (enExample)
JP (1) JP6704420B2 (enExample)
KR (1) KR20170125942A (enExample)
CN (1) CN107428831A (enExample)
AU (1) AU2016231328B2 (enExample)
BR (1) BR112017017852A2 (enExample)
CA (1) CA2978134A1 (enExample)
DK (1) DK3265489T3 (enExample)
ES (1) ES2755449T3 (enExample)
SG (1) SG11201706657PA (enExample)
WO (1) WO2016142289A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230074641A (ko) * 2020-09-23 2023-05-30 아블레비아 바이오테크 게엠베하 자가항체-매개 병태의 예방 또는 치료를 위한 화합물
IL303089A (en) * 2020-11-24 2023-07-01 Band Therapeutics Llc Compositions and methods for treatment of bleeding disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69735421T2 (de) * 1996-04-24 2006-10-19 The Regents Of The University Of Michigan, Ann Arbor Gegen inaktivierung resistenter faktor viii
CA2465004A1 (en) * 2003-05-19 2004-11-19 National Institute For Biological Standards And Control Composition
JP2005132796A (ja) * 2003-10-31 2005-05-26 Tatsuro Irimura 肉芽組織形成性疾患の治療のための医薬組成物および方法
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
EP2662083A1 (en) * 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
EP2669679A1 (en) * 2012-05-28 2013-12-04 Universitätsklinikum Hamburg-Eppendorf Method for the detection of glycans using polypeptides comprising the CD301 carbohydrate recognition domain
US10138291B2 (en) * 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
WO2014210558A1 (en) * 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker with xten and its uses thereof

Similar Documents

Publication Publication Date Title
JP2022017333A5 (enExample)
JP2016537340A5 (enExample)
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
JP2019196365A5 (enExample)
JP2017113019A5 (enExample)
JP2016527286A5 (enExample)
JP2010534486A5 (enExample)
JP2006506942A5 (enExample)
JP2019507589A5 (enExample)
JP2020501550A5 (enExample)
JP2013127002A5 (enExample)
JP2010539921A5 (enExample)
JP2013107899A5 (enExample)
JP2015509097A5 (enExample)
EA200901491A1 (ru) Полипептиды, вариабельные домены антитела и антагонисты
JP2019510739A5 (enExample)
JP2016512213A5 (enExample)
JP2014510519A5 (enExample)
JP2017536337A5 (enExample)
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
CY1120803T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου
JP2017529870A5 (enExample)
RU2017114673A (ru) Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение